King's College London has developed an experimental drug that improves the response of chemotherapy-resistant tumors by targeting a tumor defense protein.
Ana Maria Eftene
International
Foto: Pexels.com
Always see our news on Google
The drug KCL-HO-1i developed by researchers at King's College London has the potential to transform treatments for chemotherapy-resistant cancers. It works by neutralizing the protein heme oxygenase-1 (HO-1), which helps tumors protect themselves from chemotherapy and immune system attacks. Preclinical tests have shown that the drug can make tumors more responsive to chemotherapy, even in previously resistant cases. Designed for oral administration, KCL-HO-1i could begin human clinical trials in two years, with the potential to expand its applications in oncology.
Sources
Speranță pentru bolnavii de cancer: Un nou medicament sporește eficacitatea chimioterapiei chiar și în cazul tumorilor rezistente
A apărut pastila care dezarmează cancerul! Descoperirea care ar putea rescrie regulile chimioterapiei: Chiar și cele mai rezistente tumori răspund la tratament
Latest News
18:35
Lawmakers propose allowing 16-year-old students to seek psychological counseling on their own
18:30
German investigators suspect the GRU of coordinating the logistics of an attack involving an explosives-laden drone at Leipzig Airport
18:20
Donald Trump says he could negotiate a solution for the Falkland Islands in the event of a conflict between the United Kingdom and Argentina
18:10
BRICS countries call for maximum restraint and the protection of civilians in the Middle East conflict
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
